See the DrugPatentWatch profile for icosapent
Icosapent ethyl, sold under the brand name Vascepa among others, is a prescription medication used to lower triglyceride levels in adult patients. It is a formulation of eicosapentaenoic acid (EPA), an omega-3 fatty acid [1]. While icosapent ethyl has been shown to reduce the risk of cardiovascular events in certain patient populations [2], it is essential to understand its potential side effects.
When considering the frequency of severe side effects with regular use of icosapent ethyl, it is important to note that, like any medication, it can cause adverse reactions. According to the drug's prescribing information, the most common adverse reactions associated with icosapent ethyl are injection site reactions, primarily pain, erythema, and hemorrhage [3].
However, the question asks about severe side effects. Severe side effects are typically rare and can include allergic reactions, such as rash, hives, or swelling of the face, tongue, and throat, which may cause difficulty breathing or swallowing [3]. Additionally, there have been post-marketing reports of atrial fibrillation and irregular heartbeat associated with icosapent ethyl use [3].
It is crucial to consult with a healthcare professional for personalized information regarding the safety and efficacy of icosapent ethyl. Patients should report any side effects or concerns to their healthcare provider immediately.
In summary, while icosapent ethyl can cause side effects, severe side effects are rare. Common side effects include injection site reactions, while severe side effects such as allergic reactions and irregular heartbeat are less common but require immediate medical attention if they occur.
Sources:
[1] Icosapent Ethyl. (n.d.). In DrugPatentWatch.com. Retrieved April 18, 2023, from
https://www.drugpatentwatch.com/drugs/icosapent-ethyl
[2] Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812797
[3] Vascepa (icosapent ethyl) capsules, for oral use. (2021). Retrieved April 18, 2023, from
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202657s022lbl.pdf